Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

被引：147

作者：

Abhijit Chakraborty

Stacey Tannenbaum

Christiane Rordorf

Philip J. Lowe

David Floch

Hermann Gram

Sandip Roy

机构：

[1] Novartis Institutes for BioMedical Research, East Hanover, NJ 07936-1080, One Health Plaza

[2] Novartis Pharmaceuticals Corporation, East Hanover, NJ

[3] Novartis Pharma AG, Postfach, Basel

来源：

Clinical Pharmacokinetics | 2012年 / 51卷 / 6期

关键词：

Canakinumab; Cryopyrin-associated-periodic-syndromes; Interleukin-1-beta; Monoclonal-antibodies; Pharmacokinetics; Pharmacology;

D O I：

10.2165/11599820-000000000-00000

中图分类号：

学科分类号：

摘要：

Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine. Canakinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a broad spectrum of diseases, driven by IL-1β. This paper focuses on the analysis of the pharmacokinetic and pharmacodynamic data from the canakinumab clinical development programme, describing results from the recently approved indication for the treatment of cryopyrin-associated periodic syndromes (CAPS) under the trade name ILARIS®, as well as diseases such as rheumatoid arthritis, asthma and psoriasis.Canakinumab displays pharmacokinetic properties typical of an IgG1 antibody. In a CAPS patient weighing 70kg, slow serum clearance (0.174Lday) was observed with a low total volume of distribution at steady state (6.0L), resulting in a long elimination half-life of 26 days. The subcutaneous absolute bioavailability was high (70). Canakinumab displays linear pharmacokinetics, with a dose-proportional increase in exposure and no evidence of accelerated clearance or time-dependent changes in pharmacokinetics following repeated administration was observed. The pharmacokinetics of canakinumab in various diseases (e.g. CAPS, rheumatoid arthritis, psoriasis or asthma) are comparable to those in healthy individuals. No sex-or age-related pharmacokinetic differences were observed after correction for body weight.An increase in total IL-1β was observed in both healthy subjects and all patient populations following canakinumab dosing, reflecting the ability of canakinumab to bind circulating IL-1β. The kinetics of total IL-1β along with the pharmacokinetics of canakinumab were characterized by a population-based pharmacokinetic-binding model, where the apparent in vivo dissociation constant, signifying binding affinity of canakinumab to circulating IL-1β, was estimated at 1.07±0.173nmolL in CAPS patients.During development of canakinumab a cell line change was introduced. Pharmacokinetic characterization was performed in both animals and humans to assure that this manufacturing change did not affect the pharmacokineticpharmacodynamic properties of canakinumab. © 2012 Springer International Publishing AG. All rights reserved.

引用

页码：e1 / e18

页数：17

共 39 条

[1] Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J., NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder, Immunity, 20, 3, pp. 319-325, (2004)
[2] Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., Stein L., Russo R., Goldsmith D., Dent P., Rosenberg H.F., Austin F., Remmers E.F., Balow Jr. J.E., Rosenzweig S., Komarow H., Shoham N.G., Wood G., Jones J., Mangra N., Carrero H., Adams B.S., Moore T.L., Schikler K., Hoffman H., Lovell D.J., Lipnick R., Barron K., O'Shea J.J., Kastner D.L., Goldbach-Mansky R., De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neona
[3] Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., Anderson J.P., Wanderer A.A., Firestein G.S., Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist, Lancet, 364, 9447, pp. 1779-1785, (2004)
[4] Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, Journal of Experimental Medicine, 201, 9, pp. 1479-1486, (2005)
[5] Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., Watt I., Williams B., Aitchison R., McCabe D., Musikic P., Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist, Arthritis and Rheumatism, 41, 12, pp. 2196-2204, (1998)
[6] So A., De Smedt T., Revaz S., Et al., Apilot study of IL-1 inhibition by anakinra in acute gout, Arthritis Res Ther, 9, (2007)
[7] De Kluijver J., Grunberg K., Pons D., De Klerk E.P.A., Dick C.R., Sterk P.J., Hiemstra P.S., Interleukin-1β and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects, Clinical and Experimental Allergy, 33, 10, pp. 1415-1418, (2003)
[8] Rupp J., Kothe H., Mueller A., Maass M., Dalhoff K., Imbalanced secretion of IL-1β and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients, European Respiratory Journal, 22, 2, pp. 274-279, (2003)
[9] Debets R., Hegmans J.P., Troost R.J., Et al., Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: Evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release, Eur J Immunol, 25, pp. 1624-1630, (1995)
[10] Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus, New England Journal of Medicine, 356, 15, pp. 1517-1526, (2007)

← 1 2 3 4 →